<qa>  What is the starting dose of L-NMMA determined in the Phase II portion of the studyThis is a Phase IbII study assessing the maximum tolerated dose MTD, dose-limiting toxicities DLTs, recommended Phase 2 dose RP2D, and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple negative breast cancer patients. The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel 75 and 100 mgm2 and 6 dose levels of L-NMMA 5, 7.5, 10, 12.5, 15, and 17.5 mgkg. The starting dose of L-NMMA will be 7.5 mgkg. In the Phase II portion of the study, the starting dose will be the RP2D determined in the Phase Ib portion of the study. 